Dissociation is one of the most commonly discussed effects of Spravato treatment. Spravato, or esketamine nasal spray, works differently from traditional antidepressants and can temporarily change how you experience your surroundings, thoughts, or body. While these sensations can feel unfamiliar, dissociation is a known effect of esketamine and is one reason treatment takes place under direct medical supervision.
Dissociation refers to a temporary sense of being disconnected from your surroundings, thoughts, feelings, or physical body. During Spravato treatment, it may involve changes in perception, such as feeling that time or space is distorted or that your surroundings seem less familiar than usual.
Some people may describe the experience as dreamlike or detached. Others may notice that their thoughts or sensory experiences feel different for a short period.
These effects can vary from person to person. Experiencing dissociation does not necessarily mean that something has gone wrong. It is a recognized effect of esketamine that your treatment team is prepared to monitor.
Spravato contains esketamine, which affects the brain’s glutamate system by acting as an NMDA receptor antagonist. This mechanism differs from how many conventional antidepressants work.
By influencing signaling between nerve cells, esketamine can produce changes in perception and awareness along with its therapeutic effects. The exact relationship between these temporary perceptual changes and improvement in depression is still being studied.
The important point for patients is that dissociation can occur because of the medication’s effects on the brain. It is not an indication that you are losing control or that the treatment is necessarily unsafe when administered appropriately.
There is no single way dissociation feels. The experience can range from subtle changes in perception to a stronger sense of detachment.
You might notice:
Dissociation generally occurs around the treatment period and is monitored by the healthcare team. If the sensation feels uncomfortable, communicating what you are experiencing allows your providers to respond appropriately.
At Scottsdale TMS & Spravato, each treatment begins with a medical screening and assessment of your current mood and vital signs. Spravato is then self-administered as a nasal spray while medical staff directly supervise the process.
After administration, you remain at the clinic for approximately two hours while the team monitors your vital signs and overall well-being. This observation period is an important part of safe Spravato treatment because dissociation, sedation, and other effects can occur after administration.
You are not expected to immediately return to your normal activities after receiving the medication. Once the observation period is complete, the healthcare team determines whether you are clinically stable enough to leave.
The duration and intensity of dissociation can vary between individuals and treatment sessions. Some patients experience noticeable changes for a relatively short period, while others may feel effects for longer.
Because dissociation can occur along with sedation or changes in alertness, patients are monitored for at least two hours after each Spravato administration under current FDA prescribing requirements.
You should also arrange for a responsible adult to drive you home after treatment. The Scottsdale TMS & Spravato program specifically requires patients to have transportation home following the monitored session.
Dissociation is an important consideration when determining whether Spravato is appropriate, but experiencing this potential effect does not automatically mean treatment is unsuitable.
Before treatment, your healthcare provider reviews your medical history and current condition. Patients with a history of certain psychiatric conditions may require additional assessment before receiving esketamine. The FDA prescribing information specifically recommends careful evaluation of patients with psychosis because of the potential risks associated with dissociation.
Your provider can discuss your individual risks, potential benefits, and alternatives before treatment begins.
Knowing that your perception may temporarily change can make the experience easier to understand. Follow your provider’s instructions before each session and tell the treatment team about medications, medical conditions, or previous reactions that could affect your treatment.
During the session, remain in the supervised treatment environment and communicate with your healthcare team if you experience significant discomfort or unusual symptoms. The purpose of monitoring is to provide a controlled setting where changes in your condition can be recognized and addressed.
Dr. Michael Vines and Our Team at Scottsdale TMS & Spravato provide supervised care throughout the treatment visit, from the initial assessment through the post-treatment observation period.
Spravato dissociation is a temporary change in perception or awareness that can occur because esketamine affects brain signaling. Patients may experience altered perceptions of time or space, dreamlike sensations, or feelings of detachment. Because dissociation can occur alongside sedation and other temporary effects, Spravato is administered under medical supervision with a required observation period.
Understanding what dissociation may feel like can help you approach treatment with realistic expectations. Scottsdale TMS & Spravato provides a structured treatment environment where patients can be monitored throughout each session and receive ongoing psychiatric support.
Dr. Vines has practiced psychiatry in Arizona for for over 25 years and has experience working with diverse populations that include children, adolescents, adults, geriatrics, SMI patients, and the chemically dependent.
August 28, 2026
